Clinical Trial Update: Niraparib In Recurrent IDH 1/2 Gliomas [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial update evaluating niraparib in recurrent IDH1/2-mutant gliomas, including low-grade and malignant gliomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• Idh-mutant Glioma
• Low-grade Glioma
• Malignant Glioma

Drugs mentioned

• Zejula (Niraparib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Low-grade Glioma, IDH2 Gene Mutation | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING